Ventrus Biosciences Inc Share Price Nasdaq
Equities
US9228221019
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 69.36M 5.53B |
---|---|---|---|---|---|
Net income 2024 * | -81M -6.46B | Net income 2025 * | -89M -7.1B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.85
x | P/E ratio 2025 * |
-0.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.9% |
Latest transcript on Ventrus Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Jason Okazaki
CEO | Chief Executive Officer | 48 | 29/03/20 |
Anuj Gaggar
CTO | Chief Tech/Sci/R&D Officer | - | 11-07 |
William Delaney
CTO | Chief Tech/Sci/R&D Officer | 52 | 31/05/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Mahony
BRD | Director/Board Member | 60 | 13/12/17 |
Gina Consylman
BRD | Director/Board Member | 52 | 19/10/20 |
William Ringo
CHM | Chairman | 78 | 30/06/14 |
1st Jan change | Capi. | |
---|---|---|
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B | |
+3.90% | 1.65B |